| Breast Mesh Used in Two-staged Breast Reconstruction (NCT04967976) | Tianjin Medical University Cancer Institute and Hospital | 2021-08-01 |
| Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations (NCT05507606) | Tianjin Medical University Cancer Institute and Hospital | 2021-08-01 |
| Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT) (NCT04965831) | Tianjin Medical University Cancer Institute and Hospital | 2021-08-01 |
| Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043) (NCT04846634) | Tianjin Medical University Cancer Institute and Hospital | 2021-08-01 |
| Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer (NCT04982939) | Tianjin Medical University Cancer Institute and Hospital | 2021-06-21 |
| A One-arm, Prospective Study Comparing the Effects of Different Body Composition on the Survival of Patients Undergoing Radical Concurrent Chemoradiotherapy for Esophageal Cancer (NCT04936750) | Tianjin Medical University Cancer Institute and Hospital | 2021-06-17 |
| Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (NCT04907344) | Tianjin Medical University Cancer Institute and Hospital | 2021-06-15 |
| Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations (NCT04969029) | Tianjin Medical University Cancer Institute and Hospital | 2021-06-01 |
| A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer. (NCT04733417) | Tianjin Medical University Cancer Institute and Hospital | 2021-05-26 |
| HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC (NCT05029973) | Tianjin Medical University Cancer Institute and Hospital | 2021-05-10 |
| Concurrent Chemoradiotherapy Combination With Anlotinib for Limited-stage Small Cell Lung Cancer (NCT04882033) | Tianjin Medical University Cancer Institute and Hospital | 2021-05-07 |
| Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast Cancer (NCT04900311) | Tianjin Medical University Cancer Institute and Hospital | 2021-05-01 |
| Drug-eluting Beads Bronchial Arterial Chemoembolization in Stage II-III Non-small-cell Lung Cancer Patients Failed, Refused or Ineligible to Receive Standard Treatments (NCT04825925) | Tianjin Medical University Cancer Institute and Hospital | 2021-05-01 |
| Pembrolizumab in Post Radical Operation ESCC Patients With Lymph Node Positive ( KEYSTONE-004 ) (NCT04863079) | Tianjin Medical University Cancer Institute and Hospital | 2021-05-01 |
| Immune Checkpoint Inhibitor PD-1 Antibody Combined With Chemotherapy in the Perioperative Treatment of Locally Advanced Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (NCT04908566) | Tianjin Medical University Cancer Institute and Hospital | 2021-05-01 |
| Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma (NCT04834986) | Tianjin Medical University Cancer Institute and Hospital | 2021-04-30 |
| Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic Cancer (NCT04814485) | Tianjin Medical University Cancer Institute and Hospital | 2021-04-22 |
| Efficacy and Safety of Anlotinib, Irinotecan and Temozolomide in the Treatment of Refractory or Recurrent Neuroblastoma in Children: an Open, Single Arm, Single Center, Phase II Clinical Study (NCT04842526) | Tianjin Medical University Cancer Institute and Hospital | 2021-04-12 |
| Study on the Peristaltic Direction of GI Anastomosis in Roux-en-Y Reconstruction (NCT04801459) | Tianjin Medical University Cancer Institute and Hospital | 2021-04-02 |
| An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody (NCT04866381) | Tianjin Medical University Cancer Institute and Hospital | 2021-04-01 |
| Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ Adenocarcinoma (NCT04813523) | Tianjin Medical University Cancer Institute and Hospital | 2021-04-01 |
| Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer (NCT04836728) | Tianjin Medical University Cancer Institute and Hospital | 2021-03-31 |
| Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer (NCT05035147) | Tianjin Medical University Cancer Institute and Hospital | 2021-03-25 |
| Phase Ⅱ Trial of Camrelizumab in Patients Without Distant Metastasis Nasopharyngeal Carcinoma (NCT04782765) | Tianjin Medical University Cancer Institute and Hospital | 2021-03-20 |
| Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC (NCT04797806) | Tianjin Medical University Cancer Institute and Hospital | 2021-03-12 |
| Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer (NCT04828395) | Tianjin Medical University Cancer Institute and Hospital | 2021-03-01 |
| Neoadjuvant Nab-Paclitaxel and S-1 in Resectable Pancreatic Cancer (NCT04808687) | Tianjin Medical University Cancer Institute and Hospital | 2021-03-01 |
| Efficacy and Safety of Sintilimab Combined With Regorafenib and Cetuximab / Sintilimab Combined With Regorafenib in Posterior Line Therapy of Advanced Colorectal Cancer (Regosinti) (NCT04745130) | Tianjin Medical University Cancer Institute and Hospital | 2021-03-01 |
| Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma (NCT05476380) | Tianjin Medical University Cancer Institute and Hospital | 2021-02-19 |
| Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer (NCT05085626) | Tianjin Medical University Cancer Institute and Hospital | 2021-02-08 |
| Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma (NCT04701060) | Tianjin Medical University Cancer Institute and Hospital | 2021-01-26 |
| Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer (NCT04903652) | Tianjin Medical University Cancer Institute and Hospital | 2021-01-01 |
| Toripalimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer (NCT05084677) | Tianjin Medical University Cancer Institute and Hospital | 2021-01-01 |
| A Phase III Study Comparing Total and Partial Omentectomy for Patients With Advanced Gastric Cancer (NCT04843215) | Tianjin Medical University Cancer Institute and Hospital | 2021-01-01 |
| Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (NCT04631757) | Tianjin Medical University Cancer Institute and Hospital | 2020-12-15 |
| Albumin-bound Paclitaxel Combined With Cisplatin Versus Docetaxel Combined With Cisplatin Induced Chemotherapy in Advanced Head and Neck Squamous Tummor (NCT04766827) | Tianjin Medical University Cancer Institute and Hospital | 2020-12-12 |
| A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma (NCT04696432) | Tianjin Medical University Cancer Institute and Hospital | 2020-11-27 |
| Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma (NCT05637268) | Tianjin Medical University Cancer Institute and Hospital | 2020-11-26 |
| Almonertinib With Chemotherapy in mEGFR NSCLC (NCT04646824) | Tianjin Medical University Cancer Institute and Hospital | 2020-11-19 |
| Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II Trial (NCT04553887) | Tianjin Medical University Cancer Institute and Hospital | 2020-11-01 |
| Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer (NCT04884906) | Tianjin Medical University Cancer Institute and Hospital | 2020-11-01 |
| Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy (NCT04582955) | Tianjin Medical University Cancer Institute and Hospital | 2020-10-30 |
| TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors (NCT06487663) | Tianjin Medical University Cancer Institute and Hospital | 2020-10-27 |
| Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC (NCT04530227) | Tianjin Medical University Cancer Institute and Hospital | 2020-09-25 |
| Conversion Therapy of Hyperthermic Intraperitoneal Chemotherapy Plus Chemotherapy and Chemotherapy in Stage IV Gastric Cancer (NCT05228743) | Tianjin Medical University Cancer Institute and Hospital | 2020-09-01 |
| Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001) (NCT04389177) | Tianjin Medical University Cancer Institute and Hospital | 2020-07-08 |
| Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric Cancer (NCT04354662) | Tianjin Medical University Cancer Institute and Hospital | 2020-05-25 |
| Prevention and Treatment of Pyrrolitinib-associated Diarrhea (NCT04736186) | Tianjin Medical University Cancer Institute and Hospital | 2020-05-16 |
| A Single Arm Study of Brain Metastasis in Patients With HER2-positive Breast Cancer (NCT04767828) | Tianjin Medical University Cancer Institute and Hospital | 2020-05-01 |
| A Multicenter, Open and Observational Real World Study on the Prognosis and Treatment in Young Women With Breast Cancer (NCT04970264) | Tianjin Medical University Cancer Institute and Hospital | 2020-04-01 |
| Bovine Pericardial Patch and TiLOOP® Bra Mesh in Immediate Implant Breast Reconstruction. (NCT04245930) | Tianjin Medical University Cancer Institute and Hospital | 2020-01-01 |
| To Compare the Effect of Different Nutritional Pathways on Improving Nutritional Status of Esophageal Cancer Patients Undergoing Chemoradiotherapy (NCT04199832) | Tianjin Medical University Cancer Institute and Hospital | 2019-12-20 |
| PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC (NCT04273100) | Tianjin Medical University Cancer Institute and Hospital | 2019-11-14 |
| Mecapegfilgrastim Prevents Neutropenia and Radiation Esophagitis (NCT04171986) | Tianjin Medical University Cancer Institute and Hospital | 2019-11-10 |
| Efficacy and Safety of Neo-CRT Followed Surgery Compared With Definitive CRT in Patients With Initial Unresectable ESO (NCT04137679) | Tianjin Medical University Cancer Institute and Hospital | 2019-11-01 |
| Ear Acupuncture Preventing Delayed Gastric Emptying. (NCT04118881) | Tianjin Medical University Cancer Institute and Hospital | 2019-10-10 |
| Clinical Application of Nutrition Support Package Before Hepatectomy (NCT04218253) | Tianjin Medical University Cancer Institute and Hospital | 2019-10-01 |
| Appatinib Combined With S-1 in the Treatment of Small Cell Lung Cancer (NCT04128800) | Tianjin Medical University Cancer Institute and Hospital | 2019-10-01 |
| Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation (NCT04063462) | Tianjin Medical University Cancer Institute and Hospital | 2019-10-01 |
| Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in China (NCT04526028) | Tianjin Medical University Cancer Institute and Hospital | 2019-09-13 |
| Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790M (NCT04029350) | Tianjin Medical University Cancer Institute and Hospital | 2019-07-31 |
| Pegylated Liposomal Doxorubicin or Epirubicin in Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer. (NCT03983096) | Tianjin Medical University Cancer Institute and Hospital | 2019-07-07 |
| Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations. (NCT03992885) | Tianjin Medical University Cancer Institute and Hospital | 2019-07-01 |
| Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Advanced Lung Cancer (NCT03944980) | Tianjin Medical University Cancer Institute and Hospital | 2019-06-01 |
| Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLC (NCT04193098) | Tianjin Medical University Cancer Institute and Hospital | 2019-06-01 |
| Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma (NCT03987698) | Tianjin Medical University Cancer Institute and Hospital | 2019-06-01 |
| Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC (NCT03987867) | Tianjin Medical University Cancer Institute and Hospital | 2019-06-01 |
| Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer (NCT03950154) | Tianjin Medical University Cancer Institute and Hospital | 2019-06-01 |
| Study of SHR-1210 Combined With Apatinib in the Treatment of Sarcoma (NCT04126993) | Tianjin Medical University Cancer Institute and Hospital | 2019-06-01 |
| Apatinib Combined With Chemotherapy in the Treatment of Soft Tissue Sarcoma (NCT04126811) | Tianjin Medical University Cancer Institute and Hospital | 2019-06-01 |
| Chemotherapy Combined With Apatinib and PD-1 Antibody (NCT05025033) | Tianjin Medical University Cancer Institute and Hospital | 2019-05-30 |
| Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer (NCT04267549) | Tianjin Medical University Cancer Institute and Hospital | 2019-05-01 |
| Sintilimab Combined With Metformin in First-Line Chemotherapy Refractory Advanced NSCLC Patients (NCT03874000) | Tianjin Medical University Cancer Institute and Hospital | 2019-03-08 |
| Outcome of Resection for Colorectal Cancer (NCT03837782) | Tianjin Medical University Cancer Institute and Hospital | 2019-02-15 |
| Effect of Radiation and Its Timing on Breast Reconstruction in Chinese Patients (NCT03743324) | Tianjin Medical University Cancer Institute and Hospital | 2019-01-01 |
| A Trial of Total Versus Partial Omentectomy for Advanced Gastric Cancer in Gastrectomy (NCT04108494) | Tianjin Medical University Cancer Institute and Hospital | 2019-01-01 |
| PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer (NCT05035381) | Tianjin Medical University Cancer Institute and Hospital | 2019-01-01 |
| Long-Term Survival With Lenvatinib-Based Therapy in Unresectable Liver Cancer (NCT07298538) | Tianjin Medical University Cancer Institute and Hospital | 2019-01-01 |
| Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection (NCT03779035) | Tianjin Medical University Cancer Institute and Hospital | 2018-12-15 |
| Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC (NCT03736837) | Tianjin Medical University Cancer Institute and Hospital | 2018-12-01 |
| A Study to Compare Efficacy and Safety of DRT VS CRT Plus Surgery in Patients Who Achieved CCR for Esophageal Cancer (NCT03708042) | Tianjin Medical University Cancer Institute and Hospital | 2018-12-01 |
| A Efficacy and Safety Study of Composite Gel Containing Black Raspberry Extract in Removing HPV From Patients With Cervical Intraepithelial Neoplasia(CIN) After Cervical Conization (NCT03745846) | Tianjin Medical University Cancer Institute and Hospital | 2018-12-01 |
| Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC. (NCT06190652) | Tianjin Medical University Cancer Institute and Hospital | 2018-10-13 |
| Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC (NCT03671265) | Tianjin Medical University Cancer Institute and Hospital | 2018-09-17 |
| Application of Intra-operative Prophylactic Antibiotics/Antiseptics in Chinese Breast Reconstruction Patients (NCT03742908) | Tianjin Medical University Cancer Institute and Hospital | 2018-06-16 |
| The MDA Test to Differentiate of Benign and Malignant Pulmonary Nodules (NCT03790735) | Tianjin Medical University Cancer Institute and Hospital | 2018-05-03 |
| The Criteria for Lymph Node Sorting for Pathological Examination in Gastric Cancer (NCT03478449) | Tianjin Medical University Cancer Institute and Hospital | 2018-04-01 |
| The Exploratory Study of Electroacupuncture in the Treatment of Peripheral Neuropathy Induced by Platinum Based Chemotherapy Drugs (NCT03048591) | Tianjin Medical University Cancer Institute and Hospital | 2018-02-10 |
| Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Advanced ESC (NCT03366883) | Tianjin Medical University Cancer Institute and Hospital | 2018-02-01 |
| XELOX/mFOLFOX Plus Vitamin D3 vs. XELOX/mFOLFOX as Firstline Chemotherapy in mCRC (NCT03389659) | Tianjin Medical University Cancer Institute and Hospital | 2018-02-01 |
| Neck Dissection vs Radiotherapy for Cervical Metastases in Advanced Hypopharyngeal Cancer (NCT03367884) | Tianjin Medical University Cancer Institute and Hospital | 2018-01-01 |
| The Technical Operations And Standard Clinical Application Protocol of CBBCT in Diagnostic Process of Breast Cancer (NCT03861221) | Tianjin Medical University Cancer Institute and Hospital | 2018-01-01 |
| XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma (NCT03355612) | Tianjin Medical University Cancer Institute and Hospital | 2017-12-20 |
| Radiotherapy vs Neck Dissection for Clinical T1/2N0 Supraglottic Cancer (NCT03358602) | Tianjin Medical University Cancer Institute and Hospital | 2017-12-20 |
| Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer (NCT03359694) | Tianjin Medical University Cancer Institute and Hospital | 2017-12-01 |
| Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma (NCT03398122) | Tianjin Medical University Cancer Institute and Hospital | 2017-11-14 |
| Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer (NCT03348098) | Tianjin Medical University Cancer Institute and Hospital | 2017-09-06 |
| Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC (NCT03222440) | Tianjin Medical University Cancer Institute and Hospital | 2017-07-19 |
| Irinotecan-Eluting Bead (DEBIRI) for Patients With Liver Metastases From Colorectal Cancer (NCT03175016) | Tianjin Medical University Cancer Institute and Hospital | 2017-06-20 |
| Mesylate Apatinib for Stage Ⅳ STS After Failure of Chemotherapy (NCT03121846) | Tianjin Medical University Cancer Institute and Hospital | 2017-05-01 |